DIA/FDA: Revitalizing Productivity in Drug Development

DIA/FDA: Revitalizing Productivity in Drug Development October 23-24 | Bethesda, MD Explore Initiatives that Champion Research & Development Productivity Review the status quo of the pharmaceutical industry and explore the initiatives that champion the continued revitalization of R&D productivity in drug development. This two-day conference will provide a forum for industry, regulators, and academia to come together to discuss challenges and opportunities, share visions, experiences, and lessons learned, as well as successes and failures in the challenging journey of drug development.   Keynote Speakers: Keynote Address I - Revitalizing R&D: What Could We Be Doing Differently? Robert J. Temple, MD, Deputy Center Director for Clinical Science, CDER, FDA   Keynote Address II - An Overview of the Future for Drug Development Under the New Imperatives Delivered by Both Commercial and Regulatory Pressures Stephen A. Arlington, PhD, Partner, Global Pharmaceutical and Life Sciences, Advisory Services Leader, PricewaterhouseCoopers LLP   Keynote Address III - How Do We Revitalize R&D in New Drug Development? Frank W. Rockhold, PhD, Senior Vice President, Global Clinical Safety and Pharmacovigilance, GlaxoSmithKline   Keynote Address IV - Collaborative Approaches to Advancing Clinical Development Charles G. Beever, MBA, Vice President, Booz and Company    Program Overview | Register Now